South Korea · Delayed Price · Currency is KRW Cell Biotech Statistics
Total Valuation
Cell Biotech has a market cap or net worth of KRW 111.76 billion. The enterprise value is 17.45 billion.
| Market Cap | 111.76B |
| Enterprise Value | 17.45B |
Important Dates
The next estimated earnings date is Thursday, August 13, 2026.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | Dec 29, 2025 |
Share Statistics
Cell Biotech has 6.84 million shares outstanding. The number of shares has decreased by -0.08% in one year.
| Current Share Class | 6.84M |
| Shares Outstanding | 6.84M |
| Shares Change (YoY) | -0.08% |
| Shares Change (QoQ) | -0.00% |
| Owned by Insiders (%) | 35.31% |
| Owned by Institutions (%) | 8.74% |
| Float | 4.43M |
Valuation Ratios
The trailing PE ratio is 8.33.
| PE Ratio | 8.33 |
| Forward PE | n/a |
| PS Ratio | 1.98 |
| PB Ratio | 0.84 |
| P/TBV Ratio | 0.85 |
| P/FCF Ratio | 18.70 |
| P/OCF Ratio | 8.45 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 1.31, with an EV/FCF ratio of 2.92.
| EV / Earnings | 1.30 |
| EV / Sales | 0.31 |
| EV / EBITDA | 1.31 |
| EV / EBIT | 1.79 |
| EV / FCF | 2.92 |
Financial Position
The company has a current ratio of 10.50, with a Debt / Equity ratio of 0.00.
| Current Ratio | 10.50 |
| Quick Ratio | 9.92 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.02 |
| Debt / FCF | 0.05 |
| Interest Coverage | 372.02 |
Financial Efficiency
Return on equity (ROE) is 10.46% and return on invested capital (ROIC) is 21.72%.
| Return on Equity (ROE) | 10.46% |
| Return on Assets (ROA) | 4.41% |
| Return on Invested Capital (ROIC) | 21.72% |
| Return on Capital Employed (ROCE) | 7.32% |
| Weighted Average Cost of Capital (WACC) | 6.70% |
| Revenue Per Employee | 559.35M |
| Profits Per Employee | 132.74M |
| Employee Count | 101 |
| Asset Turnover | 0.41 |
| Inventory Turnover | 3.13 |
Taxes
In the past 12 months, Cell Biotech has paid 2.06 billion in taxes.
| Income Tax | 2.06B |
| Effective Tax Rate | 13.33% |
Stock Price Statistics
The stock price has increased by +24.85% in the last 52 weeks. The beta is 0.44, so Cell Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.44 |
| 52-Week Price Change | +24.85% |
| 50-Day Moving Average | 16,015.20 |
| 200-Day Moving Average | 13,803.20 |
| Relative Strength Index (RSI) | 43.66 |
| Average Volume (20 Days) | 37,666 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Cell Biotech had revenue of KRW 56.49 billion and earned 13.41 billion in profits. Earnings per share was 1,959.71.
| Revenue | 56.49B |
| Gross Profit | 41.02B |
| Operating Income | 9.74B |
| Pretax Income | 15.47B |
| Net Income | 13.41B |
| EBITDA | 13.34B |
| EBIT | 9.74B |
| Earnings Per Share (EPS) | 1,959.71 |
Balance Sheet
The company has 94.60 billion in cash and 293.41 million in debt, with a net cash position of 94.31 billion or 13,779.85 per share.
| Cash & Cash Equivalents | 94.60B |
| Total Debt | 293.41M |
| Net Cash | 94.31B |
| Net Cash Per Share | 13,779.85 |
| Equity (Book Value) | 133.03B |
| Book Value Per Share | 19,438.61 |
| Working Capital | 96.81B |
Cash Flow
In the last 12 months, operating cash flow was 13.22 billion and capital expenditures -7.25 billion, giving a free cash flow of 5.98 billion.
| Operating Cash Flow | 13.22B |
| Capital Expenditures | -7.25B |
| Depreciation & Amortization | 3.60B |
| Net Borrowing | -613.89M |
| Free Cash Flow | 5.98B |
| FCF Per Share | 873.11 |
Margins
Gross margin is 72.61%, with operating and profit margins of 17.24% and 23.73%.
| Gross Margin | 72.61% |
| Operating Margin | 17.24% |
| Pretax Margin | 27.38% |
| Profit Margin | 23.73% |
| EBITDA Margin | 23.61% |
| EBIT Margin | 17.24% |
| FCF Margin | 10.58% |
Dividends & Yields
This stock pays an annual dividend of 600.00, which amounts to a dividend yield of 3.67%.
| Dividend Per Share | 600.00 |
| Dividend Yield | 3.67% |
| Dividend Growth (YoY) | 33.33% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 22.97% |
| Buyback Yield | 0.08% |
| Shareholder Yield | 3.76% |
| Earnings Yield | 12.00% |
| FCF Yield | 5.35% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Cell Biotech has an Altman Z-Score of 8.1 and a Piotroski F-Score of 5.
| Altman Z-Score | 8.1 |
| Piotroski F-Score | 5 |